Repligen (RGEN) Earning Somewhat Positive Media Coverage, Study Finds

Media headlines about Repligen (NASDAQ:RGEN) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Repligen earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.197102560471 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Repligen stock opened at $49.27 on Friday. Repligen has a 12 month low of $29.56 and a 12 month high of $50.00. The company has a market capitalization of $2.17 billion, a P/E ratio of 71.41, a PEG ratio of 3.29 and a beta of 0.72.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.02). Repligen had a net margin of 13.49% and a return on equity of 5.05%. The firm had revenue of $47.73 million during the quarter, compared to analysts’ expectations of $45.84 million. During the same quarter in the previous year, the company posted $0.20 EPS. Repligen’s revenue for the quarter was up 47.0% on a year-over-year basis. equities analysts expect that Repligen will post 0.71 EPS for the current year.

Several research firms recently commented on RGEN. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Friday, May 18th. Stephens upped their price objective on Repligen from $50.00 to $55.00 and gave the company an “average” rating in a research note on Tuesday, July 10th. BidaskClub upgraded Repligen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 19th. ValuEngine upgraded Repligen from a “hold” rating to a “buy” rating in a research note on Thursday, June 28th. Finally, Citigroup upped their price objective on Repligen from $45.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, July 20th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $46.86.

In other Repligen news, CEO Anthony Hunt sold 16,249 shares of the stock in a transaction on Monday, May 21st. The stock was sold at an average price of $42.53, for a total transaction of $691,069.97. Following the sale, the chief executive officer now owns 243,144 shares in the company, valued at $10,340,914.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Roy T. Eddleman sold 4,770 shares of the stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $49.05, for a total value of $233,968.50. Following the sale, the insider now owns 413,985 shares in the company, valued at approximately $20,305,964.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,943 shares of company stock worth $7,636,280. Company insiders own 1.40% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Further Reading: Earnings Per Share (EPS) Explained

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply